Research programme: estrogen receptor-alpha antagonists - SumitomoAlternative Names: ER-alpha antagonists research programme - Sumitomo; Estrogen receptor-alpha antagonists - Sumitomo; Research programme: ER-alpha antagonists - Sumitomo; TM 0001; TM 0002
Latest Information Update: 30 Aug 2007
At a glance
- Originator Sumitomo Pharmaceuticals
- Mechanism of Action Estrogen receptor agonists; Estrogen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 10 Feb 1999 Preclinical development for Postmenopausal osteoporosis in Japan (PO)